JAGUAR HEALTH, INC. Capital Expenditures
JAGUAR HEALTH, INC. (JAGX) reported Capital Expenditures of $16.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-04-07
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $16.00K.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $77.00K, a 1183.33% increase from fiscal 2021.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $6.00K, a 14.29% decline from fiscal 2020.
- JAGUAR HEALTH, INC. payments to acquire property, plant, and equipment for fiscal 2020 was $7.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | $0.00 derived: sum of 2 quarters · filed 2026-04-07 | $16.00K 10-K · filed 2026-04-07 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $16.00K 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $16.00K 10-Q · filed 2025-08-14 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $3.00K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $3.00K derived: sum of 3 quarters · filed 2024-04-01 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $3.00K derived: sum of 2 quarters · filed 2024-04-01 | $77.00K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $77.00K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $74.00K 10-Q · filed 2023-08-14 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $6.00K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $6.00K 10-Q · filed 2022-08-22 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $7.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | $0.00 derived: sum of 2 quarters · filed 2021-11-17 | $7.00K 10-Q · filed 2021-11-17 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $7.00K 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $7.00K 10-Q · filed 2021-05-17 | ||||
| 2019-06-30 | $7.00K 10-Q · filed 2020-08-13 | $6.51K 10-Q · filed 2019-08-14 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $0.00 derived: sum of 2 quarters · filed 2020-04-03 | $0.00 derived: sum of 3 quarters · filed 2020-04-03 | $6.53K 10-K · filed 2020-04-03 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $6.53K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $6.53K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $6.53K 10-Q · filed 2019-05-21 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $5.94K derived: sum of 2 quarters · filed 2018-04-09 | $18.48K derived: sum of 3 quarters · filed 2018-04-09 | $104.21K 10-K · filed 2018-04-09 | |
| 2016-09-30 | $5.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $18.48K derived: sum of 2 quarters · filed 2017-11-20 | $104.21K 10-Q · filed 2017-11-20 | $104.21K derived: sum of 4 quarters · filed 2017-11-20 | |
| 2016-06-30 | $12.54K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | $98.27K 10-Q · filed 2017-08-09 | $98.27K derived: sum of 3 quarters · filed 2017-08-09 | ||
| 2016-03-31 | $85.72K 10-Q/A · filed 2017-06-23 | $85.72K derived: sum of 2 quarters · filed 2017-06-23 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $23.30K 10-K · filed 2017-02-15 | |||
| 2015-09-30 | $23.30K 10-Q · filed 2016-11-14 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $0.00 derived: sum of 2 quarters · filed 2016-03-29 | $55.15K 10-K · filed 2016-03-29 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $55.15K 10-Q · filed 2015-11-13 | |||
| 2014-06-30 | $55.15K 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |